Skip to main content
. 2019 Mar 18;120(8):791–796. doi: 10.1038/s41416-019-0428-3

Fig. 1.

Fig. 1

Diagram showing patient treatment assignment, baseline epidermal growth factor receptor (EGFR) status, and sample availability. All patients had first-line epidermal growth factor receptor tyrosine kinase inhibitor resistance. EGFR mutation status assessed by plasma or tissue test: T790M+ detected, T790M− not detected, T790M? unknown